Working... Menu
Trial record 9 of 12 for:    Gantenerumab

A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01656525
Recruitment Status : Completed
First Posted : August 3, 2012
Last Update Posted : September 19, 2014
Information provided by (Responsible Party):
Chugai Pharmaceutical

Brief Summary:
Objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary pharmacodynamic effects of multiple doses of Gantenerumab in subject with mild to moderate AD.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: Gantenerumab Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients
Study Start Date : June 2012
Actual Primary Completion Date : March 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: Gantenerumab
75 mg subcutaneous doses every 4 weeks for 24 weeks

Experimental: 2 Drug: Gantenerumab
105 mg subcutaneous doses every 4 weeks for 24 weeks

Experimental: 3 Drug: Gantenerumab
225 mg subcutaneous doses every 4 weeks for 24 weeks

Experimental: 4 Drug: Placebo
subcutaneous doses every 4 weeks for 24 weeks

Primary Outcome Measures :
  1. Number of participants with Adverse Events [ Time Frame: 36 weeks ]
  2. Pharmacokinetic parameters of Gantenerumab in plasma [ Time Frame: 36 weeks ]
  3. CSF/plasma ratios of Gantenerumab. [ Time Frame: Baseline, Day183 ]

Secondary Outcome Measures :
  1. Change from baseline in plasma Abeta [ Time Frame: Baseline,Day183 ]
  2. Change from baseline in plasma and CSF tau [ Time Frame: Baseline,Day183 ]
  3. Change from baseline in Mini-Mental State Examination (MMSE) and Alzheimer's disease assessment scale cognitive behaviors (ADAS-Cog). [ Time Frame: Baseline,Day85, 197, 253 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a diagnosis of probable AD dementia, based on NINCDS/ADRDA criteria
  • Meet DSM-IV criteria for Dementia of the Alzheimer type
  • MMSE score : 16 to 26 etc.

Exclusion Criteria:

  • Meet the exclusion criteria of MRI at screening.
  • A history of significant neurodegenerative diseases or dementia other than Alzheimer's disease.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01656525

Layout table for location information
Kansai region
Kansai, Japan
Kanto region,
Kanto, Japan
Kyushu region
Kyushu, Japan
Tokai region
Toakai, Japan
Tohoku region
Tohoku, Japan
Sponsors and Collaborators
Chugai Pharmaceutical

Layout table for additonal information
Responsible Party: Chugai Pharmaceutical Identifier: NCT01656525     History of Changes
Other Study ID Numbers: JP22431
JapicCTI-121849 ( Registry Identifier: JAPIC )
First Posted: August 3, 2012    Key Record Dates
Last Update Posted: September 19, 2014
Last Verified: September 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs